First randomized, placebo-controlled trial of inhaled rhGM-CSF in aPAP patients.
Inhaled rhGM-CSF (molgramostim) in the first randomised, double-blind, placebo-controlled, international trial in patients with autoimmune pulmonary alveolar proteinosis (aPAP).